Investors Buy High Volume of ArriVent BioPharma Call Options (NASDAQ:AVBP)

ArriVent BioPharma, Inc. (NASDAQ:AVBP) was the recipient of unusually large options trading activity on Friday. Stock traders purchased 1,832 call options on the stock. This represents an increase of 321% compared to the average daily volume of 435 call options.

ArriVent BioPharma Price Performance

Shares of NASDAQ AVBP opened at $23.43 on Friday. The company has a market cap of $967.19 million, a price-to-earnings ratio of -5.31 and a beta of 0.99. The stock’s 50-day moving average is $22.20 and its two-hundred day moving average is $20.92. ArriVent BioPharma has a 1-year low of $15.47 and a 1-year high of $27.22.

ArriVent BioPharma (NASDAQ:AVBP) last announced its quarterly earnings data on Thursday, March 5th. The company reported ($0.78) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.87) by $0.09. Equities research analysts anticipate that ArriVent BioPharma will post -2.74 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of ArriVent BioPharma in a report on Wednesday, January 21st. HC Wainwright lifted their price target on shares of ArriVent BioPharma from $42.00 to $44.00 and gave the company a “buy” rating in a research report on Friday. BTIG Research started coverage on ArriVent BioPharma in a report on Wednesday, December 10th. They issued a “buy” rating and a $45.00 price objective on the stock. Citigroup increased their price objective on ArriVent BioPharma from $31.00 to $33.00 and gave the stock a “buy” rating in a research report on Friday. Finally, Truist Financial began coverage on ArriVent BioPharma in a research report on Tuesday, November 25th. They issued a “buy” rating and a $43.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, ArriVent BioPharma has an average rating of “Moderate Buy” and a consensus price target of $41.11.

Institutional Investors Weigh In On ArriVent BioPharma

Large investors have recently modified their holdings of the company. Bessemer Group Inc. purchased a new position in ArriVent BioPharma in the third quarter valued at $26,000. Mirae Asset Global Investments Co. Ltd. lifted its holdings in ArriVent BioPharma by 27.9% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,006 shares of the company’s stock worth $40,000 after buying an additional 438 shares during the last quarter. Russell Investments Group Ltd. boosted its position in shares of ArriVent BioPharma by 9,747.6% during the 3rd quarter. Russell Investments Group Ltd. now owns 2,068 shares of the company’s stock worth $38,000 after acquiring an additional 2,047 shares in the last quarter. BNP Paribas Financial Markets boosted its position in shares of ArriVent BioPharma by 31.0% during the 2nd quarter. BNP Paribas Financial Markets now owns 2,571 shares of the company’s stock worth $56,000 after acquiring an additional 609 shares in the last quarter. Finally, Group One Trading LLC purchased a new position in shares of ArriVent BioPharma in the 4th quarter valued at about $57,000. 9.48% of the stock is owned by hedge funds and other institutional investors.

Key ArriVent BioPharma News

Here are the key news stories impacting ArriVent BioPharma this week:

• Positive Sentiment: Oppenheimer reaffirmed an “outperform” rating and raised its price target to $50 (from $44), a large upside vs. the current price. Oppenheimer boosts PT to $50
• Positive Sentiment: Citigroup raised its price target from $31 to $33 and kept a “buy” rating, signaling more analyst conviction. Citigroup raises PT to $33
• Positive Sentiment: HC Wainwright raised its target from $42 to $44 and maintained a “buy” rating—another analyst upgrade supporting upside. HC Wainwright raises PT to $44
• Positive Sentiment: Unusually large options activity: traders bought about 1,832 call contracts (≈321% above typical call volume), indicative of short-term bullish positioning.
• Positive Sentiment: Quarterly EPS beat: AVBP reported loss-per-share of ($0.78) vs. consensus ($0.87), a small beat that reduces near-term execution risk. Quarterly results press release
• Neutral Sentiment: Company released full-year 2025 financial results and highlighted progress; no headline surprises were reported in the summary notice. Full-year 2025 results
• Neutral Sentiment: Consensus brokerage coverage remains constructive (“Moderate Buy”), reflecting overall analyst support but not an immediate catalyst. Consensus recommendation coverage
• Neutral Sentiment: Reported short-interest entries show inconsistent/zero values (data artifact), so there’s no clear evidence of rising short pressure based on the published figures.
• Negative Sentiment: Despite the bullish signals above, AVBP is trading down on heavy volume — likely profit-taking, option-driven hedging flows, or broader market weakness outweighing analyst upgrades in the near term. Investors should watch intraday volume, near-term option activity, and any sector-wide moves for further direction.

ArriVent BioPharma Company Profile

ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002.